PI3K-p110δ 参与慢性淋巴细胞白血病巨噬细胞的抗体应答
研究探讨慢性淋巴细胞白血病(CLL)患者单核细胞来源巨噬细胞的 Fcγ 受体信号,发现 I 类 PI3K 催化亚基 p110δ 对巨噬细胞应答治疗性抗体至关重要;抑制 p110δ 可减少 FcγR 介导的抗体免疫应答,且该信号通路不依赖 SYK 和 BTK 活性。
要点
- p110δ 是 CLL 巨噬细胞应答治疗性抗体的关键分子。
- 抑制 p110δ 可降低 FcγR 介导的抗体免疫应答。
- FcγR 下游信号可不依赖 SYK 和 BTK 活性。
核心结论
- CLL 巨噬细胞的 FcγR 抗体应答通过一条此前未识别的 p110δ 依赖通路进行,该通路独立于 SYK/BTK 激活通路。
研究设计与样本
- 研究使用 CLL 患者单核细胞来源巨噬细胞,检测 FcγR 信号及 p110δ 抑制对治疗性抗体应答的影响。
主要发现
- p110δ 对 CLL 来源巨噬细胞应答治疗性抗体必不可少。
- 抑制巨噬细胞中的 p110δ 可减少 FcγR 介导的抗体免疫应答。
- FcγR 下游信号独立于 SYK 和 BTK 活性。
临床怎么用
- p110δ 通路可能作为改善 CLL 治疗性抗体应答的潜在靶点。
- 评估 FcγR 信号时需考虑不依赖 SYK/BTK 的 p110δ 依赖机制。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Fcγ receptor (FcγR) signalling in monocyte derived macrophages from chronic lymphocytic leukaemia (CLL) patients is poorly understood. This signalling pathway is the key determinant of the ability of the macrophages to respond to therapeutic antibodies in current clinical use for CLL. Muted FcγR signalling activity accompanies disease progression and results in resistance to therapeutic antibodies. The molecular mechanisms controlling FcγR signalling and resistance are unknown. Here, we demonstrate that the class I phosphoinositide 3-kinase (PI3K) catalytic subunit p110δ is essential for CLL-derived macrophages to respond to therapeutic antibodies. Inhibition of p110δ in the macrophages reduces FcγR-mediated antibody immune responses. Surprisingly, our studies indicated that FcγR downstream signalling is independent of SYK and BTK activity. Thus, we show that FcγR antibody responses occur via a previously unidentified p110δ-dependent pathway, which is independent of the previously described SYK/BTK activation pathway. These data provide novel insights into the effectors of antibody responses. Our data also provide mechanistic insights into therapy resistance in CLL.
引用
- Enya Chen YC, Burgess M, Mapp S, et al. PI3K-p110δ contributes to antibody responses by macrophages in chronic lymphocytic leukemia. Leukemia. 2019. PMID: 31462739. doi:10.1038/s41375-019-0556-z
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。